United States Biotechnology & Medical Research

Nektar Therapeutics (NKTR)

Track

Over the past 90 days, Nektar Therapeutics insiders have engaged in 15 transactions, all of which were sales. Key executives, including the CEO and Chief R&D Officer, executed planned and proposed sales totaling approximately $4.3 million. These transactions occurred following the company's recent earnings report, amid a 19.5% decline in stock price over the same period.
Ticker: NKTR Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Nektar Therapeutics. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Zalevsky Jonathan
Chief R&D Officer
1 sale — total 100,000 USD
Planned sale 30 Jun 2026
Value US$4,074,562.60 | Price 382.07 | Shares 80,621
Proposed sale 30 Jun 2026
Value US$3,567,379.53 | Price 311.89 | Shares 53,159
Proposed sale 30 Jun 2026
Value US$4,264,429.47 | Price 329.54 | Shares 20,411
Planned sale 17 Jun 2026
Value US$277,425.00 | Price 61.65 | Shares 4,500
Planned sale 17 Jun 2026
Value US$334,455.00 | Price 60.81 | Shares 5,500
Proposed sale 17 Jun 2026
Value US$602,700.00 | Price 60.27 | Shares 10,000
Planned sale 16 Jun 2026
Value US$285,154.87 | Price 60.71 | Shares 4,697
Planned sale 16 Jun 2026
Value US$318,020.91 | Price 59.97 | Shares 5,303
Proposed sale 16 Jun 2026
Value US$609,600.00 | Price 60.96 | Shares 10,000
Planned sale 15 Jun 2026
Value US$336,211.98 | Price 60.71 | Shares 5,538
Proposed sale 15 Jun 2026
Value US$328,846.44 | Price 59.38 | Shares 5,538
Sale 19 May 2026
Value US$29,086.44 | Price 65.51 | Shares 444
Proposed sale 19 May 2026
Value US$29,084.53 | Price 65.51 | Shares 444
Sale 19 May 2026
Value US$13,036.49 | Price 65.51 | Shares 199
Proposed sale 19 May 2026
Value US$13,035.63 | Price 65.51 | Shares 199
Proposed sale 13 Mar 2026
Value US$5,702,966.40 | Price 72.64 | Shares 78,510
Sale 18 Feb 2026
Value US$13,140.00 | Price 73.00 | Shares 180
Proposed sale 18 Feb 2026
Value US$13,139.68 | Price 73.00 | Shares 180
Sale 18 Feb 2026
Value US$30,879.00 | Price 73.00 | Shares 423
Proposed sale 18 Feb 2026
Value US$30,878.24 | Price 73.00 | Shares 423
Planned sale 20 Jan 2026
Value US$137,935.89 | Price 35.67 | Shares 3,867
Proposed sale 20 Jan 2026
Value US$137,946.37 | Price 35.67 | Shares 3,867
Proposed sale 25 Nov 2025
Value US$129,812.21 | Price 58.82 | Shares 2,207
Sale 25 Nov 2025
Value US$119,795.96 | Price 54.28 | Shares 2,207
Proposed sale 25 Nov 2025
Value US$37,055.59 | Price 58.82 | Shares 630
Sale 25 Nov 2025
Value US$34,196.40 | Price 54.28 | Shares 630
Proposed sale 25 Nov 2025
Value US$68,052.89 | Price 58.82 | Shares 1,157
Sale 25 Nov 2025
Value US$62,801.96 | Price 54.28 | Shares 1,157
Planned sale 9 Sep 2025
Value US$58,297.80 | Price 48.18 | Shares 1,210
Planned sale 9 Sep 2025
Value US$102,388.44 | Price 47.49 | Shares 2,156
Planned sale 9 Sep 2025
Value US$55,692.00 | Price 46.41 | Shares 1,200
Planned sale 9 Sep 2025
Value US$94,836.00 | Price 45.16 | Shares 2,100
Proposed sale 9 Sep 2025
Value US$311,204.76 | Price 46.69 | Shares 6,666
Planned sale 5 Sep 2025
Value US$45,315.04 | Price 39.89 | Shares 1,136
Planned sale 5 Sep 2025
Value US$86,413.32 | Price 38.82 | Shares 2,226
Planned sale 5 Sep 2025
Value US$125,122.48 | Price 37.87 | Shares 3,304
Proposed sale 5 Sep 2025
Value US$256,837.92 | Price 38.53 | Shares 6,666
Planned sale 4 Sep 2025
Value US$40,597.20 | Price 35.80 | Shares 1,134
Planned sale 4 Sep 2025
Value US$21,087.20 | Price 34.40 | Shares 613
Planned sale 4 Sep 2025
Value US$50,175.84 | Price 33.54 | Shares 1,496
Planned sale 4 Sep 2025
Value US$62,247.51 | Price 32.37 | Shares 1,923
Proposed sale 4 Sep 2025
Value US$174,119.16 | Price 33.70 | Shares 5,166
Planned sale 4 Sep 2025
Value US$10,956.83 | Price 35.69 | Shares 307
Planned sale 4 Sep 2025
Value US$6,503.49 | Price 34.41 | Shares 189
Planned sale 4 Sep 2025
Value US$14,515.20 | Price 33.60 | Shares 432
Planned sale 4 Sep 2025
Value US$25,716.99 | Price 32.43 | Shares 793
Proposed sale 4 Sep 2025
Value US$57,688.44 | Price 33.52 | Shares 1,721
Planned sale 2 Sep 2025
Value US$45,240.00 | Price 30.16 | Shares 1,500
Proposed sale 2 Sep 2025
Value US$45,243.50 | Price 30.16 | Shares 1,500
Planned sale 2 Sep 2025
Value US$14,598.50 | Price 30.10 | Shares 485
Proposed sale 2 Sep 2025
Value US$14,600.10 | Price 30.10 | Shares 485
Sale 19 Aug 2025
Value US$19,277.75 | Price 26.59 | Shares 725
Proposed sale 19 Aug 2025
Value US$19,277.83 | Price 26.59 | Shares 725
Sale 19 Aug 2025
Value US$17,974.84 | Price 26.59 | Shares 676
Proposed sale 19 Aug 2025
Value US$17,974.90 | Price 26.59 | Shares 676
Sale 19 Aug 2025
Value US$41,826.07 | Price 26.59 | Shares 1,573
Proposed sale 19 Aug 2025
Value US$41,826.23 | Price 26.59 | Shares 1,573
Sale 19 May 2025
Value US$7,177.04 | Price 0.67 | Shares 10,712
Proposed sale 19 May 2025
Value US$7,190.96 | Price 0.67 | Shares 10,712
Sale 19 May 2025
Value US$15,549.36 | Price 0.67 | Shares 23,208
Proposed sale 19 May 2025
Value US$15,579.54 | Price 0.67 | Shares 23,208
Sale 19 May 2025
Value US$6,697.32 | Price 0.67 | Shares 9,996
Proposed sale 19 May 2025
Value US$6,710.32 | Price 0.67 | Shares 9,996
Sale 19 Feb 2025
Value US$11,150.40 | Price 1.01 | Shares 11,040
Proposed sale 19 Feb 2025
Value US$11,137.16 | Price 1.01 | Shares 11,040
Sale 19 Feb 2025
Value US$10,403.00 | Price 1.01 | Shares 10,300
Proposed sale 19 Feb 2025
Value US$10,390.64 | Price 1.01 | Shares 10,300
Sale 19 Feb 2025
Value US$24,011.74 | Price 1.01 | Shares 23,774
Proposed sale 19 Feb 2025
Value US$23,983.21 | Price 1.01 | Shares 23,774
Proposed sale 24 Dec 2024
Value US$14,801.33 | Price 0.89 | Shares 16,560
Sale 24 Dec 2024
Value US$14,738.40 | Price 0.89 | Shares 16,560
Sale 23 Dec 2024
Value US$30,061.80 | Price 0.90 | Shares 33,402
Proposed sale 23 Dec 2024
Value US$29,898.13 | Price 0.90 | Shares 33,402
Sale 19 Dec 2024
Value US$48,048.10 | Price 0.94 | Shares 51,115
Proposed sale 19 Dec 2024
Value US$48,063.43 | Price 0.94 | Shares 51,115
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-02 2026-06-30 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
80,621 -10.2%
382.07
US$4,074,563 		80,621 -10.2% 382.07 US$4,074,563
2026-06-30 2026-06-30 PrS Proposed sale
3.8
JONATHAN ZALEVSKY

Officer

Officer
53,159
311.89
US$3,567,380 		53,159 311.89 US$3,567,380
2026-06-30 2026-06-30 PrS Proposed sale
3.8
JONATHAN ZALEVSKY

Officer

Officer
20,411
329.54
US$4,264,429 		20,411 329.54 US$4,264,429
2026-06-18 2026-06-17 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
4,500 -7.6%
61.65
US$277,425 		4,500 -7.6% 61.65 US$277,425
2026-06-18 2026-06-17 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
5,500 -8.5%
60.81
US$334,455 		5,500 -8.5% 60.81 US$334,455
2026-06-17 2026-06-17 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
10,000
60.27
US$602,700 		10,000 60.27 US$602,700
2026-06-18 2026-06-16 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
4,697 -6.7%
60.71
US$285,155 		4,697 -6.7% 60.71 US$285,155
2026-06-18 2026-06-16 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
5,303 -7.1%
59.97
US$318,021 		5,303 -7.1% 59.97 US$318,021
2026-06-16 2026-06-16 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
10,000
60.96
US$609,600 		10,000 60.96 US$609,600
2026-06-17 2026-06-15 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
5,538 -26.4%
60.71
US$336,212 		5,538 -26.4% 60.71 US$336,212
2026-06-15 2026-06-15 PrS Proposed sale
3.8
JONATHAN ZALEVSKY

Officer

Officer
5,538
59.38
US$328,846 		5,538 59.38 US$328,846
2026-05-21 2026-05-19 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
444 -0.6%
65.51
US$29,086 		444 -0.6% 65.51 US$29,086
2026-05-21 2026-05-19 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
199 -0.9%
65.51
US$13,036 		199 -0.9% 65.51 US$13,036
2026-05-19 2026-05-19 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
199
65.51
US$13,036 		199 65.51 US$13,036
2026-05-19 2026-05-19 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
444
65.51
US$29,085 		444 65.51 US$29,085
2026-03-13 2026-03-13 PrS Proposed sale
4.0
Wilson Mark Andrew

Former Officer

Officer
78,510
72.64
US$5,702,966 		78,510 72.64 US$5,702,966
2026-02-20 2026-02-18 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
180 -0.8%
73.00
US$13,140 		180 -0.8% 73.00 US$13,140
2026-02-20 2026-02-18 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
423 -0.6%
73.00
US$30,879 		423 -0.6% 73.00 US$30,879
2026-02-18 2026-02-18 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
423
73.00
US$30,878 		423 73.00 US$30,878
2026-02-18 2026-02-18 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
180
73.00
US$13,140 		180 73.00 US$13,140
2026-01-22 2026-01-20 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
3,867 -15.3%
35.67
US$137,936 		3,867 -15.3% 35.67 US$137,936
2026-01-20 2026-01-20 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
3,867
35.67
US$137,946 		3,867 35.67 US$137,946
2025-11-25 2025-11-25 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
2,207
58.82
US$129,812 		2,207 58.82 US$129,812
2025-11-25 2025-11-25 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
630
58.82
US$37,056 		630 58.82 US$37,056
2025-11-25 2025-11-25 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
1,157
58.82
US$68,053 		1,157 58.82 US$68,053
2025-11-25 2025-11-25 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
630 -2.8%
54.28
US$34,196 		630 -2.8% 54.28 US$34,196
2025-11-25 2025-11-25 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
2,207 -3.9%
54.28
US$119,796 		2,207 -3.9% 54.28 US$119,796
2025-11-25 2025-11-25 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
1,157 -5.7%
54.28
US$62,802 		1,157 -5.7% 54.28 US$62,802
2025-09-11 2025-09-09 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,210 -2.4%
48.18
US$58,298 		1,210 -2.4% 48.18 US$58,298
2025-09-11 2025-09-09 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
2,156 -4.1%
47.49
US$102,388 		2,156 -4.1% 47.49 US$102,388
2025-09-11 2025-09-09 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,200 -2.2%
46.41
US$55,692 		1,200 -2.2% 46.41 US$55,692
2025-09-11 2025-09-09 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
2,100 -3.7%
45.16
US$94,836 		2,100 -3.7% 45.16 US$94,836
2025-09-09 2025-09-09 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
6,666
46.69
US$311,205 		6,666 46.69 US$311,205
2025-09-08 2025-09-05 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,136 -2.0%
39.89
US$45,315 		1,136 -2.0% 39.89 US$45,315
2025-09-08 2025-09-05 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
2,226 -3.7%
38.82
US$86,413 		2,226 -3.7% 38.82 US$86,413
2025-09-08 2025-09-05 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
3,304 -5.3%
37.87
US$125,122 		3,304 -5.3% 37.87 US$125,122
2025-09-05 2025-09-05 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
6,666
38.53
US$256,838 		6,666 38.53 US$256,838
2025-09-08 2025-09-04 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,134 -1.8%
35.80
US$40,597 		1,134 -1.8% 35.80 US$40,597
2025-09-08 2025-09-04 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
613 -1.0%
34.40
US$21,087 		613 -1.0% 34.40 US$21,087
2025-09-08 2025-09-04 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,496 -2.3%
33.54
US$50,176 		1,496 -2.3% 33.54 US$50,176
2025-09-08 2025-09-04 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,923 -2.8%
32.37
US$62,248 		1,923 -2.8% 32.37 US$62,248
2025-09-08 2025-09-04 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
307 -1.7%
35.69
US$10,957 		307 -1.7% 35.69 US$10,957
2025-09-08 2025-09-04 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
189 -1.1%
34.41
US$6,503 		189 -1.1% 34.41 US$6,503
2025-09-08 2025-09-04 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
432 -2.3%
33.60
US$14,515 		432 -2.3% 33.60 US$14,515
2025-09-08 2025-09-04 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
793 -4.1%
32.43
US$25,717 		793 -4.1% 32.43 US$25,717
2025-09-04 2025-09-04 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
5,166
33.70
US$174,119 		5,166 33.70 US$174,119
2025-09-04 2025-09-04 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
1,721
33.52
US$57,688 		1,721 33.52 US$57,688
2025-09-04 2025-09-02 PlS Planned sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,500 -2.2%
30.16
US$45,240 		1,500 -2.2% 30.16 US$45,240
2025-09-04 2025-09-02 PlS Planned sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
485 -2.5%
30.10
US$14,598 		485 -2.5% 30.10 US$14,598
2025-09-02 2025-09-02 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
485
30.10
US$14,600 		485 30.10 US$14,600
2025-09-02 2025-09-02 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
1,500
30.16
US$45,244 		1,500 30.16 US$45,244
2025-08-21 2025-08-19 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
725 -3.6%
26.59
US$19,278 		725 -3.6% 26.59 US$19,278
2025-08-21 2025-08-19 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
676 -3.2%
26.59
US$17,975 		676 -3.2% 26.59 US$17,975
2025-08-21 2025-08-19 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
1,573 -2.2%
26.59
US$41,826 		1,573 -2.2% 26.59 US$41,826
2025-08-19 2025-08-19 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
1,573
26.59
US$41,826 		1,573 26.59 US$41,826
2025-08-19 2025-08-19 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
676
26.59
US$17,975 		676 26.59 US$17,975
2025-08-19 2025-08-19 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
725
26.59
US$19,278 		725 26.59 US$19,278
2025-05-21 2025-05-19 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
10,712 -3.4%
0.67
US$7,177 		10,712 -3.4% 0.67 US$7,177
2025-05-21 2025-05-19 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
23,208 -2.1%
0.67
US$15,549 		23,208 -2.1% 0.67 US$15,549
2025-05-21 2025-05-19 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
9,996 -3.1%
0.67
US$6,697 		9,996 -3.1% 0.67 US$6,697
2025-05-19 2025-05-19 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
10,712
0.67
US$7,191 		10,712 0.67 US$7,191
2025-05-19 2025-05-19 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
9,996
0.67
US$6,710 		9,996 0.67 US$6,710
2025-05-19 2025-05-19 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
23,208
0.67
US$15,580 		23,208 0.67 US$15,580
2025-02-21 2025-02-19 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
11,040 -3.3%
1.01
US$11,150 		11,040 -3.3% 1.01 US$11,150
2025-02-21 2025-02-19 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
10,300 -3.2%
1.01
US$10,403 		10,300 -3.2% 1.01 US$10,403
2025-02-21 2025-02-19 S Sale
3.9
ROBIN HOWARD W

President & CEO

Executive Director
23,774 -2.1%
1.01
US$24,012 		23,774 -2.1% 1.01 US$24,012
2025-02-19 2025-02-19 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
11,040
1.01
US$11,137 		11,040 1.01 US$11,137
2025-02-19 2025-02-19 PrS Proposed sale
3.9
ROBIN HOWARD W

Officer; Director

Executive Director
23,774
1.01
US$23,983 		23,774 1.01 US$23,983
2025-02-19 2025-02-19 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
10,300
1.01
US$10,391 		10,300 1.01 US$10,391
2024-12-26 2024-12-24 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
16,560
0.89
US$14,801 		16,560 0.89 US$14,801
2024-12-26 2024-12-24 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
16,560 -4.7%
0.89
US$14,738 		16,560 -4.7% 0.89 US$14,738
2024-12-26 2024-12-23 S Sale
4.0
Wilson Mark Andrew

Chief Legal Officer

Officer
33,402 -8.7%
0.90
US$30,062 		33,402 -8.7% 0.90 US$30,062
2024-12-23 2024-12-23 PrS Proposed sale
4.0
Wilson Mark Andrew

Officer

Officer
33,402
0.90
US$29,898 		33,402 0.90 US$29,898
2024-12-20 2024-12-19 S Sale
3.8
Zalevsky Jonathan

Chief R&D Officer

Officer
51,115 -13.5%
0.94
US$48,048 		51,115 -13.5% 0.94 US$48,048
2024-12-19 2024-12-19 PrS Proposed sale
3.8
Zalevsky Jonathan

Officer

Officer
51,115
0.94
US$48,063 		51,115 0.94 US$48,063
Explore more

More insider trading research around Nektar Therapeutics

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America